Boston Immunotechnology and Therapeutics announced today that it has entered into an exclusive option and licensing agreement with Baiji Shenzhou to develop and commercialize Boston Immune's innovative tumor necrotizing group 2 (TNFR2) antibody.
has obtained exclusive licenses to develop, produce and commercialize TNFR2 antibodies (BITR2101) in Asia (excluding Japan), Australia and New Zealand.
the two companies plan to conduct Phase I clinical trials of BITR2101, including a combination with the anti-PD-1 antibody tislezumab in Baiji Shenzhou. Russell LaMontagne, chief executive of Boston Immune, said:
The state is a global pharmaceutical company with a strong track record and an ideal partner to help develop the research TNFR2 antibody BITR2101.
the collaboration with Baiji Shenzhou is a powerful validation of the Boston Immune antibody platform and an opportunity to demonstrate the potential of BITR2101 as a single drug and in collaboration with the immuno-checkpoint inhibitor tislezumab."
TNFR2 is a member of the TNF-subject super family, which is highly expressed in many tumor types and has been shown to promote tumor cell growth.
TNFR2 is also expressed on inhibitory immune cells in tumor micro-environments, including regulatory T-cells (Tregs) and inhibitory cells from myelin-like sources.
TNFR2 has been identified as a potential driver of immune escape and tumor development, as well as immune checkpoint inhibitor resistance.